Glucagon in Beta-Blocker Toxicity
For beta-blocker overdose with bradycardia or hypotension, administer glucagon as a 50 mcg/kg IV bolus (typically 3-5 mg in adults) followed by a continuous infusion of 1-15 mg/hour, titrated to clinical response, while recognizing that high-dose insulin is the preferred first-line therapy for refractory hypotension. 1
Treatment Algorithm for Beta-Blocker Toxicity
First-Line Therapy
- High-dose insulin is the Class 1 recommendation for hypotension refractory to or used in conjunction with vasopressors 1
- Vasopressors should be administered for hypotension (Class 1 recommendation) 1
Glucagon as Adjunctive Therapy
It is reasonable to use glucagon (Class 2a recommendation) for bradycardia or hypotension due to beta-blocker poisoning 1. The 2023 AHA guidelines position glucagon as a reasonable option but not the primary intervention, reflecting the evolution in toxicology management.
Specific Glucagon Dosing
Loading Dose
- 50 mcg/kg IV bolus over 2 minutes 2, 3
- In a typical 70 kg adult, this equals approximately 3.5 mg
- This is substantially higher than the 1 mg dose used for hypoglycemia 4
Maintenance Infusion
- 1-15 mg/hour continuous infusion, titrated to patient response 2
- Start at the lower end and titrate upward based on hemodynamic response
- Infusion may be preferable to repeated boluses as it provides more sustained hemodynamic effects 3
Clinical Evidence for Dosing
A 2020 randomized trial demonstrated that high-dose glucagon (50 mcg/kg bolus) increased heart rate by 13 beats per minute, systolic blood pressure by 15.6 mmHg, and cardiac output by 18% regardless of beta-blockade status 3. However, a 2023 case series found more modest effects with only a 4 bpm increase in heart rate, suggesting variable clinical response 5.
Mechanism and Rationale
Glucagon bypasses the beta-adrenergic receptor by directly activating adenylyl cyclase, increasing intracellular cAMP. This mechanism explains why it can work despite complete beta-receptor blockade 2. The drug increases:
- Heart rate
- Myocardial contractility
- Atrioventricular conduction
Critical Adjunctive Measures
Antiemetic Prophylaxis
Pretreat with ondansetron or other antiemetics before glucagon administration. Despite prophylaxis, 80% of patients experienced nausea in controlled trials 3, and 6-10% experienced vomiting in clinical practice 5. This is dose-dependent and nearly universal at high doses.
Dextrose Supplementation
- Monitor glucose levels closely
- Approximately 10% of patients develop hyperglycemia 5
- Have dextrose available as beta-blocker toxicity can paradoxically cause hypoglycemia, which glucagon may initially mask
Electrolyte Monitoring
- Monitor potassium levels for hypokalemia 2
- Check frequently during high-dose infusions
Important Caveats and Limitations
Modest Clinical Effects
The actual hemodynamic improvements with glucagon are often modest and of uncertain clinical significance 5. A multi-center case series of 107 patients showed only a 4 bpm increase in heart rate and 4.5 mmHg increase in systolic blood pressure—statistically significant but clinically underwhelming.
Comparative Efficacy
Animal studies show no survival benefit of glucagon over vasopressin in beta-blocker toxicity 6. This supports the guideline recommendation that vasopressors remain essential therapy.
Cost and Availability
High-dose glucagon therapy is expensive and may have limited availability, requiring 3-15 vials per hour for continuous infusion 2. This practical limitation may influence treatment decisions.
Contraindications (from FDA labeling)
- Pheochromocytoma (risk of hypertensive crisis) 4
- Insulinoma (risk of rebound hypoglycemia) 4
- Known hypersensitivity to glucagon 4
Refractory Cases
If glucagon, high-dose insulin, and vasopressors fail:
- VA-ECMO is reasonable for life-threatening beta-blocker poisoning with cardiogenic shock refractory to pharmacological interventions (Class 2a) 1
- Hemodialysis may be reasonable specifically for atenolol or sotalol poisoning (Class 2b) 1
- Intravenous lipid emulsion is NOT recommended (Class 3: No Benefit) 1
Practical Implementation
- Recognize severe beta-blocker toxicity (bradycardia, hypotension, cardiogenic shock)
- Initiate vasopressors and high-dose insulin as primary therapy
- Administer antiemetic prophylaxis
- Give glucagon 50 mcg/kg IV bolus over 2 minutes
- Start continuous infusion at 1-5 mg/hour
- Titrate infusion up to 15 mg/hour based on response
- Monitor for nausea, vomiting, hyperglycemia, and hypokalemia
- Consider VA-ECMO early if refractory to pharmacologic therapy
The key paradigm shift is that glucagon is no longer considered first-line therapy—high-dose insulin has supplanted it based on superior evidence for improving inotropy in cardiogenic shock from beta-blocker poisoning 1.